ScreenerHero

DYN Dyne Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · dyne-tx.com
15.97USD+3.70%Mkt Cap: 2.98B $P/E: —

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.98B USD
Enterprise Value2.21B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-446.21M USD
Revenue/Share—
Last Price15.97 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees289
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.62
PEG—
EV/EBITDA-4.13
EV/Revenue—
P/S—
P/B3.63
EPS (TTM)-3.30
EPS (Forward)-3.34
52W Range
11.9226% of range27.30
52W High27.30 USD
52W Low11.92 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-37.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-403.21M USD
CapEx (TTM)20.71M USD
FCF Margin—
FCF Yield-10.63%
Net Debt-665.13M USD
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.17
Current Ratio12.02
Quick Ratio11.52
Book Value/Sh4.24 USD
Cash/Share4.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.00 USD
Upside (mean)+125.4%
Target Range10.00 USD – 50.00 USD
10.00+125.4% to mean50.00
# Analysts15
Ownership
Shares Out.186.75M
Float186.24M
Insiders0.24%
Institutions103.68%
Short Interest
Short Ratio8.0d
Short % Float16.01%
Short % Out.12.52%
Shares Short23.38M
Short (prev mo.)21.46M
Technical
SMA 5022.34 (-28.5%)
SMA 20019.59 (-18.5%)
Beta1.12
S&P 52W Chg16.45%
Avg Vol (30d)3.21M
Avg Vol (10d)2.97M
Technical Indicators
RSI (14)28.9
MACD-1.9345
MACD Signal-2.0330
MACD Hist.+0.0985
BB Upper19.74 USD
BB Middle16.96 USD
BB Lower14.18 USD
BB Width32.77%
ATR (14)0.9883 USD
Vol Ratio (20d)0.86x